Cardiol Therapeutics Inc.

Company Overview

Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases.

The Company brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific Advisory Board comprising business and thought leaders with extensive industry experience and expertise in commercializing prescription medicines.

Cardiol’s lead product candidate, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being clinically developed for use in cardiovascular medicine.

The Corporation has also received Investigational

New Drug Application (“IND”) authorization from the United States Food and Drug Administration (“FDA”) to conduct a Phase II multi-national, randomized, double-blind, placebo- controlled trial designed to evaluate the efficacy and safety of CardiolRx™ in acute myocarditis. This disease remains an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people less than 35 years of age. The Corporation believes there is a significant opportunity to develop CardiolRx™ as an orphan drug for the treatment of acute myocarditis, for which there is currently no accepted standard of care.

The Corporation has also received an IND authorization by the FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance and safety of CardiolRx™ in patients with recurrent pericarditis. The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRx™. Recurrent pericarditis is the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue. Further, up to 50% of patients with a recurrent episode of pericarditis experience more recurrences. Recurrent pericarditis is an orphan disease in the United States, thereby making CardiolRx™ eligible for orphan drug status under the FDA’s Orphan Drug Designation program.

NASDAQ : CRDL
TSX : CRDL

Stock Quote

OPPORTUNITIES

We have selected a range of direct investment opportunities to meet your needs.

Looking for more info? Request a free callback or check out our support base to find our frequently ask question

Subscribe to all the latest new and insights to the financial markets with our monthly Corporate newsletter

Loading